CN104829554B - Phenothiazine compound and its preparation method and application - Google Patents

Phenothiazine compound and its preparation method and application Download PDF

Info

Publication number
CN104829554B
CN104829554B CN201510271507.5A CN201510271507A CN104829554B CN 104829554 B CN104829554 B CN 104829554B CN 201510271507 A CN201510271507 A CN 201510271507A CN 104829554 B CN104829554 B CN 104829554B
Authority
CN
China
Prior art keywords
dried
added
product
compound
spin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201510271507.5A
Other languages
Chinese (zh)
Other versions
CN104829554A (en
Inventor
李高全
谢爱云
张翠芳
陈毛芬
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dalian University of Technology
Original Assignee
Dalian University of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dalian University of Technology filed Critical Dalian University of Technology
Priority to CN201510271507.5A priority Critical patent/CN104829554B/en
Publication of CN104829554A publication Critical patent/CN104829554A/en
Application granted granted Critical
Publication of CN104829554B publication Critical patent/CN104829554B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/18—[b, e]-condensed with two six-membered rings
    • C07D279/22—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom
    • C07D279/24—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom with hydrocarbon radicals, substituted by amino radicals, attached to the ring nitrogen atom
    • C07D279/28—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom with hydrocarbon radicals, substituted by amino radicals, attached to the ring nitrogen atom with other substituents attached to the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/18—[b, e]-condensed with two six-membered rings
    • C07D279/22—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The present invention relates to a kind of preparation methods of the phenothiazine compound with antitumaous effect and the compound, moreover, it relates to application and such compound anticancer drug as active ingredient of such compound in preparing anticancer drug.The present invention to phenthazine ternary chain of rings parent nucleus by being modified to obtain the compound with broad spectrum anticancer effect, and synthetic method is simple, yield is high；Such phenothiazine compounds has certain inhibiting effect for Breast cancer lines MCF 7 and human hepatoma cell strain Hep G2, and the new drug to meet clinical demand provides new approaches.

Description

Phenothiazine compound and its preparation method and application
Technical field
The invention belongs to anticancer drug fields, are related to a kind of phenothiazine compound with antitumaous effect and the compound Preparation method, moreover, it relates to application of such compound in preparing anticancer drug, and contain such chemical combination Anticancer drug of the object as active ingredient.
Background technology
Past, the cancer stem cell of various solid tumors and leukemia was also separated successively over more than 20 years.Cancer stem cell (CSC：CancerStemCell) refer to sub-fraction cell subsets (about 0.1%-5%) in tumour cell, have and be similar to The feature of stem cell has the characteristics that self-renewing, infinite multiplication and high oncogenicity, most of (G in a dormant state0), With extremely strong drug resistance, traditional chemotherapy or radiotherapy cannot kill it, eventually lead to tumor recurrence and transfer.From 2009 The hoary hair research institute of Harvard University and the Massachusetts Institute of Technology killed with salinomycin the experiment made on the living of breast carcinoma stem cell It rises, the research of small molecule anti-cancer disease stem cell drugs is developed rapidly.So far, have nearly 30 anticancer stem cells Drug is pushed to clinical one, two, three phases.
Phenothiazines be widely used, a kind of more mature antipsychotic class drug, mainly act on maincenter Dopamine receptor, have the effects that calm, town spits, antipsychotic and reduces body temperature.Recent studies indicate that phenothiazines Drug has the function of inhibiting tumor stem cell.United States Patent (USP) US2013/0065887A1 discloses a kind of for treating acute bone The dopamine-receptor antagonist of myelogenous leukemia, the antagonist are phenothiazines thioridazine or chlorine pyridazine, are had Targeting is selected, leukemia stem cell can be targetedly damaged and other cells not encroached on.At phenothiazines In the research for managing lymphoma cell, display is had been reported that, under clinical common dose, chlorpromazine and triperazine can promote lymph The apoptosis of oncocyte and on normal lymphocytes without influence.Chinese patent application CN104114175 discloses dry for removing cancer The medical composition of cell, the composition, which includes phenothiazines such as triperazine, can inhibit lung cancer stem cell.In the past Research it has also been found that schizophreniac to suffer from cancer probability low compared with normal person, it is potential anti-swollen to also confirm that such compound has Tumor effect.The above evidence shows that phenothiazine compound and its derivative have and inhibits tumor proliferation or inhibition Tumor Stem The effect of cell.Thus industry worker is had become for the research of phenothiazine compound its broad spectrum anticancer effect to make great efforts specially to grind One of direction, with wide spectrum, efficiently, where the novel phenothiazines of low toxicity are research hotspot, design and screen tool There are this kind anti-cancer drugs of new chemical constitution, novel mechanism or new role target position to become urgent problem to be solved.
Invention content
The present inventor synthesizes by research and screening to phenothiazine compound structure-activity relationship with antitumaous effect Phenothiazine compound, it is demonstrated experimentally that the compound is equal for MCF-7 cell strainHJ2mm and Human hepatoma cell line Hep-G2 There is certain inhibiting effect.
The technical proposal of the invention is realized in this way：A kind of phenothiazine compound, the compound structure such as general formula (I) It is shown：
Wherein, A is piperazinyl, piperidyl, triazol radical, tetrazole base, pyrrole radicals, guanidine radicals, morpholinyl and its derivative Group；R is C2-3Straight chain saturated alkyl；B can be independently Cl, methyl mercapto or trifluoromethyl.
Further, when B is methyl mercapto, A is piperazinyl, triazol radical, tetrazole base, pyrrole radicals, guanidine radicals, morpholinyl And its derivatives group or piperidyl or N (CH3)2；When B is trifluoromethyl, A is morpholinyl, piperidyl, pyrrole radicals and its spreads out Biological group or piperazinyl；When B be Cl when, A be piperidyl, triazol radical, tetrazole base, pyrrole radicals, guanidine radicals, morpholinyl and Its derivatives group or piperazinyl.
The preparation method of above-mentioned phenothiazine compound is also claimed in the present invention, and presoma has the chemistry of general formula (II) Substitution reaction occurs in organic solvent for structure, T1 groups and the ligand groups of the presoma；Wherein T1Selected from halogenopropane and Its derivatives group, T2Selected from Cl, methyl mercapto or trifluoromethyl；
The ligand groups include：Piperidyl, piperazinyl, triazol radical, tetrazole base, pyrrole radicals, guanidine radicals, morpholinyl And its derivatives group.
Another kind prepare above-mentioned phenothiazine compound method be：M is with the compound with general formula (III) organic molten Substitution reaction occurs in agent；
Wherein, M is selected from the halothane and its derivative replaced by piperidyl or derivatives thereof group, and B can be independent For Cl, methyl mercapto or trifluoromethyl.
Piperidyl, piperazinyl and its derivatives group of above method formula of (I) or (II) are by one or two continuous Amino acid is connected by amidation or esterification.
Further, the organic solvent such as ether, alkane, aromatic hydrocarbon, amides, nitrile, amine, alcohols or ketone is molten The mixture of one kind or above-mentioned solvent in agent, such as THF, toluene, DMF, acetonitrile, triethylamine, acetone or alcohol.
The present invention provides the new application of above-mentioned phenothiazine compound.
On the one hand, the phenothiazine compound is used to prepare the drug of anti-human breast cancer cell line mcf-7.
On the other hand, the phenothiazine compound is used to prepare the drug of anti-human liver cancer cell strain Hep-G2.
A kind of anticancer pharmaceutical composition, wherein the mixture conduct for containing any compound of above-mentioned phenothiazines or they has Imitate ingredient and one or more pharmaceutically acceptable carriers.
Further, which can be made the pharmaceutically acceptable dosage form of any type, injection, spraying Agent, inhalant or oral agents.
The part particular compound of the present invention is as shown in table 1.
1 compound list of table
The above-mentioned phenothiazine compound that the present invention synthesizes, synthetic method is simple, yield is high, by connecting to phenthazine ternary Ring parent nucleus 10,2 modified, obtain have with desired broad spectrum anticancer effect, such phenothiazine compounds is for people Breast cancer cell line mcf-7 and Human hepatoma cell line Hep-G2 have certain inhibiting effect, to meet the new drug of clinical demand New approaches are provided.
Specific implementation mode
Below by specific embodiment, the present invention will be described, but the present invention is not limited thereto.In following embodiments The experimental method is unless otherwise specified conventional method；The reagent and biomaterial unless otherwise specified can be from Commercial sources obtain.
Embodiment 1：Prepare 2-21-2
2-10：
It takes 2- trifluoromethyls phenthazine (2.00g, 7.4831mmol) to be placed in 500mL flasks, is added through anhydrous K2CO3It is dry Dry THF (100mL), then in N260% NaH mineral oil (1.1973g, 29.9323mmol) and 1- are sequentially added under protection Bromo- 3- chloropropanes (2.9601mL, 29.9323mmol) are refluxed overnight in 65 DEG C of bath temperatures.It is cooled to room temperature, then by reaction solution It pours into mixture of ice and water, is extracted with ethyl acetate (300mL+100mL × 2), merge organic phase, with anhydrous MgSO4It is dry, mistake Solid is filtered out, is then spin-dried for filtrate, adds ethyl acetate (50mL) dissolving, silica white (20g) is added into solution and revolves Dry, dry method loading crosses silica gel column purification, with ethyl acetate and petroleum ether gradient elution, collects product, is spin-dried for, vacuum drying obtains Product 2-10 (4.9444g, yield 69.8%).+c ESI Q1MS：[M+H+]344.00。
2-21-2：
Take 2-10 (250mg, 0.7272mmol) to be placed in 30mL straight tube bottles, then be added morpholine (95.0mg, 1.0908mmol), triethylamine (0.30mL, 2.1816mmol) and acetonitrile (10mL), are stirred overnight at 80 DEG C.It is cooled to room Temperature is directly spin-dried for, and crude product is dissolved with methanol, filtering, silica white is added into filtrate, solid solution, dry method loading mistake is made Silica gel column purification is collected product, is spin-dried for, is dried in vacuo to obtain product 2- with triethylamine, ethyl acetate and petroleum ether gradient elution 21-2 (108.5mg, yield 31.5%).1H-NMR(400MHz,CDCl3)δ7.23-7.10(m,4H),7.04(s,1H),7.00- 6.89 (m, 2H), 4.00 (t, J=6Hz, 2H), 3.76-3.62 (m, 4H), 2.61-2.39 (m, 6H), 2.08-1.92 (m, 2H)； +c ESI Q1MS：[M+H+]395.09。
Embodiment 2：Prepare 2-21-6
In 30mL straight tube bottles, be added 2-10 (250mg, 0.7272mmol), prolinol (110.3mg, 1.0908mmol), Triethylamine (0.5mL) and acetonitrile (10mL), are stirred overnight at 80 DEG C.It is cooled to room temperature, is directly spin-dried for, by crude product methanol Dissolving, filtering, into filtrate, solid solution is made in addition silica white, and dry method loading crosses silica gel column purification, with triethylamine, acetic acid second Ester and petroleum ether gradient elution collect product, are spin-dried for, are dried in vacuo to obtain product 2-21-6 (138.9mg, yield 38.9%).1H- NMR(400MHz,CDCl3)δ7.25-7.13(m,4H),7.05(s,1H),7.01-6.89(m,2H),4.05-3.96(m,2H), 3.68-3.60(m,1H),3.51-3.42(m,1H),3.33-3.23(m,1H),3.14-3.03(m,1H),2.81-2.69(m, 1H),2.61-2.50(m,1H),2.35-2.24(m,1H),2.16-2.05(m,2H),1.85-1.72(m,3H),1.28-1.23 (m,2H)；+c ESI Q1MS：[M+H+]409.11。
Embodiment 3：Prepare 2-163,2-172
2-21-1：
It takes 2-10 (300mg, 0.8726mmol) to be placed in 30mL straight tube bottles, 1- tert-butoxycarbonyl-piperazines is then added (243.8mg, 1.3089mmol), triethylamine (0.37ml, 2.6178mmol) and acetonitrile (10mL), reacted under the conditions of 80 DEG C Night.It being cooled to room temperature, is directly evaporated, crude product is dissolved with methanol, silica white is then added into filtrate is made solid solution, Dry method loading crosses silica gel column purification, is eluted with ethyl acetate, petroleum ether and triethylamine gradient, collects product, is spin-dried for, and is dried in vacuo Obtain product 2-21-1 (63.4mg, yield 40.2%).1H-NMR(400MHz,CDCl3)δ7.24-7.10(m,5H),7.04(s, 1H),7.00-6.88(m,1H),4.08-3.95(m,2H),3.60-3.25(m,4H),2.70-2.25(m,6H),2.12-1.90 (m,2H),1.44(s,9H)；+c ESI Q1MS：[M+H+]494.20。
2-163：
In 100mL flasks, 2-21-1 (2.4458g, 4.9569mmol) is dissolved in CH2Cl2TFA is added in (50mL) (4mL), is stirred overnight at room temperature.Concentration removes solvent and major part TFA, and crude product is dissolved with methanol, and NaHCO is then added3 Excessive TFA is neutralized, solid is filtered to remove, silica white is added into filtrate, solid solution is made, it is pure that dry method loading crosses silicagel column Change, uses NH3·H2O, CH3OH and CH2Cl2Gradient elution, collect product, be spin-dried for, be dried in vacuo product 2-163 (2.4346g, Yield 100%).1H-NMR(400MHz,CDCl3) δ=7.23-7.10 (m, 4H), 7.03 (s, 1H), 6.99-6.93 (t, J= 6Hz, 1H), 6.92-6.87 (d, J=8Hz, 1H), 3.99 (t, J=4Hz, 2H), 3.10-2.95 (m, 4H), 2.70-2.47 (m, 6H),1.95-1.86(m,2H).+c ESI Q1MS：[M+H+]394.25。
2-169：
2-163 (1.9146g, 4.8681mmol) is placed in 200mL flasks, Boc- glycine (Boc- is then added Gly) (0.9381g, 5.3549mmol), HBTU (2.7404g, 7.3022mmol), HOBT (986.7mg, 7.3022mmol) and DIEA (3.8159mL, 21.9065mmol) is added dropwise under the conditions of 0 DEG C, then moves to and is stirred overnight at room temperature by DMF (50mL).It will Reaction solution is poured into saturation NaHCO3It in solution (500mL), is extracted with ethyl acetate (500mL), water phase is extracted with ethyl acetate again Take (200mL × 3) split-phase；Merge organic phase, then with saturation NaHCO3Solution cleans (200mL × 2), then molten with saturation NaCl Liquid cleans (200mL × 2)；The anhydrous MgSO of organic phase after split-phase4It is dry, it is filtered to remove solid, silica white is added into filtrate Solid solution is made, dry method loading crosses silica gel column purification, with ethyl acetate and petroleum ether gradient elution, collects product, is spin-dried for, very Empty dry product 2-169 (2.6138g, yield 97.54%).1H-NMR(400MHz,CDCl3)δ7.21-7.10(m,4H), 7.03 (s, 1H), 6.97-6.89 (m, 2H), 3.99 (t, J=4Hz, 2H), 3.93-3.88 (d, J=4Hz, 2H), 3.56-3.51 (m, 2H), 3.29-3.24 (m, 2H), 2.48 (t, J=6Hz, 2H), 2.40-2.33 (m, 4H), 1.95-1.88 (m, 2H), 1.44 (s,9H)
2-172：
2-169 (2.5949g, 4.7140mmol) is placed in 100mL flasks, CH is then added2Cl2(20mL) dissolves, then TFA (5mL) is added to be stirred overnight.It is spin-dried for, by crude product CH3OH dissolves, and NaHCO is then added3Neutralize extra TFA；Filtering Solid is removed, filtrate is spin-dried for, crude product uses CH again2Cl2Dissolving, wet method loading cross silica gel column purification, use NH3·H2O, first Alcohol and dichloromethane carry out gradient elution, collect product, are spin-dried for, are dried in vacuo to obtain product 2-172 (1.3303g, yield 62.8%).1H-NMR(400MHz,CDCl3)δ7.22-7.11(m,4H),7.04(s,1H),6.98-6.89(m,2H),4.00 (t, J=6Hz, 2H), 3.56 (t, J=4Hz, 2H), 3.42 (s, 2H), 3.27 (t, J=4Hz, 2H), 2.49 (t, J=4Hz, 2H), 2.37 (t, J=4Hz, 4H), 1.97-1.89 (m, 2H), 1.25 (s, 2H)；+c ESI Q1MS：[M+H+]451.39。
Embodiment 4：Prepare 2-21-4,2-162
2-21-4：
With 2-10 (250mg, 0.7272mmol), piperidines -4- alcohol (110.3mg, 1.0908mmol), triethylamine (0.5mL) With acetonitrile (10mL), it is stirred overnight at 80 DEG C.It is cooled to room temperature, is directly spin-dried for, crude product is dissolved with methanol, filter, it is past Silica white is added in filtrate, solid solution is made, dry method loading crosses silica gel column purification, with triethylamine, ethyl acetate and petroleum ether ladder Degree elution, collects product, is spin-dried for, is dried in vacuo to obtain product 2-21-4 (232.5mg, yield 65.1%).1H-NMR(400MHz, CDCl3) δ 7.24-7.10 (m, 4H), 7.04 (s, 1H), 6.99-6.90 (m, 2H), 3.97 (t, J=6Hz, 2H), 3.79-3.66 (m,2H),2.82-2.72m,2H),2.60-2.50(m,2H),2.32-2.14(m,2H),1.98-1.86(m,2H),1.63- 1.50 (m, 2H), 1.14 (t, J=8Hz, 2H)；+c ESI Q1MS：[M+H+]409.13。
2-154：
2-21-4 (1.6316g, 3.9947mmol) is taken to be placed in 250mL flasks, addition Boc-Gly (839.7mg, 4.7936mmol), DMAP (48.8mg, 0.3995mmol) and CH2Cl2(200mL) is placed reaction liquid into and is stirred 30 points at 0 DEG C Clock adds DCC (2.4727g, 11.9841mmol), then goes to and be stirred overnight at room temperature.It is filtered to remove solid impurity；Add Enter methanol to dissolve crude product, silica white is added into solution, solid solution is made, dry method loading crosses silica gel column purification, uses acetic acid Ethyl ester and petroleum ether gradient elution collect product, are spin-dried for, are dried in vacuo to obtain product 2-154 (3.2987g, yield 100%).1H- NMR(400MHz,CDCl3)δ7.21-7.09(m,4H),7.04(s,1H),6.97-6.89(m,2H),4.86-4.77(m,1H), 3.96 (t, J=4Hz, 2H), 2.70-2.58 (m, 2H), 2.52-2.42 (m, 2H), 2.28-2.16 (m, 2H), 1.98-1.89 (m,4H),1.87-1.80(m,2H),1.77-1.70(m,4H),1.45(s,9H)；+c ESI Q1MS：[M+H+]551.42。
2-162：
It takes 2-154 (3.1691g, 5.6029mmol) to be placed in 100mL flasks, CH is added2Cl2(50mL) dissolves, and adds TFA (2.15mL, 28.0143mmol), is stirred overnight at room temperature.It is spin-dried for removing CH2Cl2, crude product is dissolved with methanol, is stirred Lower addition NaHCO3Extra TFA is neutralized, solid is filtered to remove, silica white is added into filtrate and is made solid solution, in dry method Sample crosses silica gel column purification, uses NH3·H2O、CH3OH and CH2Cl2Gradient elution is carried out, product is collected, is spin-dried for, is dried in vacuo to obtain production Product 2-162 (1.5027g, yield 57.7%).1H-NMR(400MHz,CDCl3)δ7.22-7.10(m,4H),7.04(s,1H), 6.98-6.90 (m, 2H), 4.84-4.75 (m, 1H), 3.96 (t, J=4Hz, 2H), 3.41 (s, 2H), 2.70-2.60 (m, 2H), 2.47 (t, J=6Hz, 2H), 2.25-2.16 (m, 2H), 1.97-1.89 (m, 2H), 1.89-1.81 (m, 2H), 1.68-1.57 (m,4H)；+c ESI Q1MS：[M+H+]466.38。
Embodiment 5：Prepare 4-215
7-78：
2- (piperidin-2-yl) ethane -1- alcohol (20.00g, 154.8947mmol) is placed in 500mL flasks, CH is added2Cl2 (300mL) dissolves, and triethylamine (45mL, 309.7894mmol) is then added, is added with stirring Boc2O(40.5669g, 185.8736mmol), it reacts 4 hours at room temperature.It is directly spin-dried for, by crude product CH3OH dissolves, and NaHCO is added3It is extra to neutralize TFA, filtering, into filtrate be added silica white solid solution is made, dry method loading crosses silica gel column purification, with ethyl acetate and stone Oily ether gradient elution, collects product, and concentration is dried in vacuo to obtain product 7-78 (36.2772g, yield 100%).ITMS+c ESI [M+H+]230.18。
7-80：
It takes 7-78 (15.00g, 65.4094mmol) to be placed in 500mL flasks, is added through anhydrous K2CO3Dry THF (150mL), triphenyl phosphorus (27.7142g, 105.6623mmol), at 0 DEG C stir under be added portionwise NBS (18.8058g, 105.6623mmol), it is transferred to and stirs 3 days at room temperature.It is directly spin-dried for, crude product CH2Cl2Dissolving, silica gel is added into solution Solid solution is made in powder, and dry method loading crosses silica gel column purification, with ethyl acetate and petroleum ether gradient elution, collects product, concentrates, It is dried in vacuo to obtain product 7-80 (12.0956g, yield 63.26%).1H-NMR(500MHz,CDCl3)δ4.44-4.35(m,1H), 4.09-3.94(m,1H),3.41-3.28(m,2H),2.80-2.66(m,1H),2.40-2.29(m,1H),1.98-1.84(m, 1H),1.76-1.61(m,3H),1.58-1.43(m,12H)。
4-197：
It takes triperazine (1.00g, 3.7415mmol) to be placed in 100mL three neck round bottom, is added through Anhydrous potassium carbonate Dried THF (50mL), in N2NaH (359.2mg, 14.966mmol), the 7- of the lower mineral oil guard for being added 60% of protection 80 (1.0975g, 3.7415mmol), are refluxed overnight under 60 DEG C of heating conditions.After reaction, stop reaction, be cooled to room Temperature pours into reaction solution in 200mL ice water, is extracted with ethyl acetate (200mL × 3), and it is dry with anhydrous magnesium sulfate to merge organic phase Dry, filtering, into filtrate, solid solution is made in addition (3g) silica white, and dry method loading crosses silica gel column purification, silicagel column：2.5× 20cm makees solvent with petroleum ether and is homogenized wet method dress post, and dry method loading collects product with ethyl acetate and petroleum ether gradient elution, It is spin-dried for, is dried in vacuo to obtain sterling 4-197 (1.40g, yield 78%).ITMS+c ESI[M+H+]479.12.4-215：
It takes 4-197 (1.30g, 2.7050mmol) to be placed in 100mL flasks, dichloromethane (50mL) is added, stirring is lower to be added Enter TFA (2.0727ml, 27.0498mmol), is stirred overnight at room temperature.It is directly evaporated, crude product is dissolved with methanol, be added NaHCO3Neutralize extra TFA；Filtering, into filtrate, solid solution is made in addition silica white, crosses silica gel column purification.Use NH3· H2O, methanol and dichloromethane gradient elution, collect product, are spin-dried for, are dried in vacuo to obtain product 4-215 (539.2mg, yield 53%).1H-NMR(500MHz,CDCl3)δ7.26-7.14(m,4H),7.10-7.07(m,1H),7.01-6.92(m,2H), 4.08-3.94(m,3H),3.12-3.02(m,1H),2.73-2.59(m,2H),1.92-1.85(m,2H),1.84-1.76(m, 1H),1.72-1.64(m,2H),1.44-1.34(m,2H)；ITMS+c ESI：[M+H+]379.20。
Embodiment 6 prepares 2-30-3
2-133：
It takes 2- methyl mercaptos phenthazine (10.00g, 40.8163mmol) to be placed in 500mL flasks, is added through anhydrous K2CO3It is dry Dry THF (250mL), in N2The NaH (6.5306g, 163.2653mmol) and 1- of the lower mineral oil guard for being added 60% of protection Bromo- 3- chloropropanes (16.15mL, 163.2653mmol), are refluxed overnight at 65 DEG C.It is cooled to room temperature, reaction solution is poured into ice In water, crude product is extracted with ethyl acetate (300mL+100mL × 2), merges the anhydrous MgSO of organic phase4It is dry, it is filtered to remove Solid is spin-dried for, and ethyl acetate (50mL) is then added and dissolves set product, silica white (20g) is added into solution, solid is made Solution.Dry method loading crosses silica gel column purification, with ethyl acetate and petroleum ether gradient elution, collects product, is spin-dried for, is dried in vacuo Product 2-133 (13.798g, yield 100%).1H-NMR(400MHz,CDCl3) δ 7.20-7.14 (m, 2H), 7.07 (d, J= 8Hz, 1H), 6.97-6.88 (m, 2H), 6.87-6.81 (m, 2H), 4.08 (t, J=6Hz, 2H), 3.67 (t, J=6Hz, 2H), 2.47(s,3H),2.27-2.21(m,2H)；+c ESI Q1MS[M+H+]322.13。
2-30-3：
With 2-133 (300mg, 0.9320mmol), dimethylamine hydrochloride (114mg, 1.3980mmol), triethylamine (0.39mL, 2.7961mmol) and acetonitrile (10mL), is stirred overnight at 80 DEG C.It is cooled to room temperature, is directly spin-dried for, by crude product Dissolved with methanol, filter, into filtrate addition silica white solid solution is made, dry method loading crosses silica gel column purification, with triethylamine, Ethyl acetate and petroleum ether gradient elution collect product, are spin-dried for, are dried in vacuo to obtain product 2-30-3 (83.2mg, yield 24.3%).1H-NMR(400MHz,CDCl3)δ7.18-7.10(m,2H),7.07-7.01(m,1H),6.94-6.86(m,2H), 6.84-6.78(m,3H),3.93-3.85(m,2H),2.46(s,3H),2.42-2.36(m,2H),2.22-2.19(s,6H), 1.98-1.90(m,2H)；+c ESI Q1MS:[M+H+]331.10,[M+NH3]347.08。
Embodiment 7 prepares 2-30-2
Take 2-133 (300mg, 0.9320mmol), morpholine (121.8mg, 1.3981mmol), triethylamine (0.39mL, 2.7961mmol) with acetonitrile (10mL), it is stirred overnight at 80 DEG C.It is cooled to room temperature, is directly spin-dried for, crude product methanol is molten Solution, filtering, into filtrate, solid solution is made in addition silica white, and dry method loading crosses silica gel column purification, with triethylamine, ethyl acetate With petroleum ether gradient elution, product is collected, is spin-dried for, is dried in vacuo to obtain product 2-30-2 (121mg, yield 33.5%).1H-NMR (400MHz,CDCl3)δ7.18-7.09(m,2H),7.08-7.01(m,1H),6.95-6.86(m,2H),6.85-6.78(m, 2H), 3.94 (t, J=6Hz, 2H), 3.71-3.61 (m, 4H), 2.51-2.34 (m, 9H), 1.99-188 (m, 2H)；+c ESI Q1MS:[M+H+]373.23。
Embodiment 8 prepares 2-30-4
With 2-133 (300mg, 0.9320mmol), piperidines -4- alcohol (141.4mg, 1.3979mmol), triethylamine (0.39mL, 2.7961mmol) and acetonitrile (10mL), is stirred overnight at 80 DEG C.It is cooled to room temperature, is directly spin-dried for, by crude product Dissolved with methanol, filter, into filtrate addition silica white solid solution is made, dry method loading crosses silica gel column purification, with triethylamine, Ethyl acetate and petroleum ether gradient elution collect product, are spin-dried for, are dried in vacuo to obtain product 2-30-4 (126.1mg, yield 35.0%).+c ESI Q1MS:[M+H+]387.16。
Embodiment 9 prepares 2-30-5
It is placed in 30ml straight tube bottles with 2-133 (300mg, 0.9320mmol), addition 1- (2- ethoxys) pyrazine (182mg, 1.3980mmol), triethylamine (0.39mL, 2.7961mmol) and acetonitrile (10mL), are stirred overnight at 80 DEG C.Stop reaction, It is cooled to room temperature, is spin-dried for, crude product is dissolved with methanol, silica white is added into filtrate, solid solution, dry method loading mistake is made Silica gel column purification is collected product, is spin-dried for, is dried in vacuo to obtain product 2- with triethylamine, ethyl acetate and petroleum ether gradient elution 30-5 (106mg, yield 27.4%).+c ESI Q1MS:[M+H+]416.15。
Embodiment 10 prepares 2-30-6
2-133 (300mg, 0.9320mmol) is taken to be placed in 30mL straight tube bottles, addition prolinol (141.4mg, 1.3979mmol), triethylamine (0.39mL, 2.7961mmol) and acetonitrile (10mL), are stirred overnight at 80 DEG C.It is cooled to room Temperature is spin-dried for, and crude product is dissolved with methanol, silica white is added into filtrate, solid solution is made, it is pure that dry method loading crosses silicagel column Change, with triethylamine, ethyl acetate and petroleum ether gradient elution, collects product, be spin-dried for, be dried in vacuo to obtain product 2-30-6 (88.3mg, yield 24.5%).+c ESI Q1MS:[M+H+]387.16。
Embodiment 11 prepares 2-58
2-133 (0.3126g, 0.9712mmol) is taken, is placed in 30mL straight tube bottles, alcohol solvent (20mL), hydrochloric acid is added NaOH (77.7mg, 1.9423mmol) is then dissolved in H by guanidine (185.5mg, 1.9423mmol)2Straight tube is added in O (1mL) In bottle, it is stirred overnight under the conditions of 80 DEG C after sealing.Wet method loading crosses silica gel column purification, with ammonium hydroxide, methanol and dichloromethane ladder Degree elution, collects product, is spin-dried for, is dried in vacuo to obtain product 2-58 (141mg, yield 38.1%).+c ESI Q1MS:[M+H+] 345.30。
Embodiment 12 prepares 2-60
2-133 (0.2964g, 0.9208mmol) is added in 30mL straight tube bottles, 1,2,4- triazoles are added (0.1272g, 1.8417mmol), K2CO3(0.7636g, 5.5250mmol), KI (15.3g, 0.09208mmol) and acetone (10mL) is stirred overnight after sealing under the conditions of 60 DEG C.Filtering, filtrate is spin-dried for, crude product is dissolved with dichloromethane, Xiang Rong Silica white is added in liquid, solid solution is made, dry method loading crosses silica gel column purification, is eluted with methanol and dichloromethane gradient, collects Product is spin-dried for, and is dried in vacuo to obtain product 2-60 (179.0mg, yield 54.8%).1H-NMR(400MHz,CDCl3)δ7.94(s, 1H),7.88(s,1H),7.24-7.10(m,3H),7.04-6.94(m,1H),6.90-6.78(m,2H),6.77-6.74(m, 1H),4.35-4.24(m,2H),3.85-3.74(m,2H),2.50-2.34(m,5H)；+c ESI Q1MS:[M+H+] 355.18, [M+Na+]377.11。
Embodiment 13 prepares 2-138
2-133 (300mg, 0.9320mmol) is added in 100ml flasks, 5- methyl-1 H- tetrazoles are added (156.6mg, 1.8640mmol), K2CO3(0.7729g, 5.5921mmol), KI (15.4mg, 0.09320mmol) and acetone (15ml).It is stirred at reflux under the conditions of 60 DEG C overnight.It is cooled to room temperature, filters, it is molten that solid is made in addition silica white into filtrate Liquid, dry method loading cross silica gel column purification, with ethyl acetate and petroleum ether gradient elution, collect product, are spin-dried for, and are dried in vacuo to obtain production Product 2-138 (71.3mg, yield 20.7%).1H-NMR(400MHz,CDCl3) δ 7.20-7.11 (m, 2H), 7.09 (d, J=8Hz, 1H), 6.97-6.92 (m, 1H), 6.89-6.80 (m, 2H), 6,76-6.74 (m, 1H), 4.68 (t, J=6Hz, 2H), 3.98 (t, J=6Hz, 2H), 2.52-2.44 (m, 8H).
Embodiment 14 prepares 2-139
2-133 (0.2964g, 0.9208mmol) is added in 100mL flasks, 1,2,3- of addition triazoles (0.11mL, 1.8640mmol), K2CO3(0.7729g, 5.5961mmol), KI (15.4mg, 0.09320mmol) and acetone (15mL).60 It is stirred at reflux under the conditions of DEG C overnight.It is cooled to room temperature, filters, silica white is added after filtrate is concentrated, solid solution, dry method is made Loading crosses silica gel column purification, with ethyl acetate and petroleum ether gradient elution, collects product, is spin-dried for, is dried in vacuo to obtain product 2-139 (202.5mg, yield 61.3%).1H-NMR(400MHz,CDCl3)δ7.59-7.58(m,2H),7.21-7.02(m,3H), 7.00-6.68 (m, 4H), 4.59 (t, J=6Hz, 2H), 4.02-3.84 (m, 2H), 2.54-2.36 (m, 5H).
Embodiment 15 prepares 2-149
2-133 (300mg, 0.9320mmol) is added in 100mL flasks, addition 1H- tetrazoles (0.1306mg, 1.8640mmol), K2CO3(0.7729g, 5.5921mmol), KI (15.4mg, 0.09320mmol) and acetone (50mL).60 It is stirred overnight under the conditions of DEG C.It is cooled to room temperature, filters, silica white is added into filtrate, solid solution is made, dry method loading crosses silicon Rubber column gel column purifies.With ethyl acetate and petroleum ether gradient elution, collect product, be spin-dried for, be dried in vacuo product 2-149 (44.1mg, Yield 13.3%).+c ESI Q1MS:[M+H+]356.13,[M+Na+]378.11。
Embodiment 16 prepares 2-72
2-30-1：
It takes 2-12 (300mg, 0.9320mmol) to be placed in 30mL straight tube bottles, 1- tert-butoxycarbonyl-piperazines is then added (260.4mg, 1.3980mmol), triethylamine (0.39mL, 2.7961mmol) and acetonitrile (10mL), after sealing under the conditions of 80 DEG C It is stirred overnight.It is cooled to room temperature, is spin-dried for, crude product is dissolved with methanol, silica white is added into filtrate, solid solution is made, do Method loading crosses silica gel column purification, with triethylamine, ethyl acetate and petroleum ether gradient elution, collects product, is spin-dried for, is dried in vacuo Product 2-30-1 (75.1mg, yield 17.08%).+c ESI Q1MS:[M+H+]472.13,[M+NH3]488.11。
2-72：
It takes 2-30-1 (75.1mg, 0.1522mmol) to be placed in 100mL flasks, CH is added2Cl2(50mL) dissolves, and adds TFA (4mL, 52.2014mmol), is stirred overnight at room temperature.It is spin-dried for, crude product is dissolved with methanol, NaHCO is then added3In With extra TFA, filtering, into filtrate, solid solution is made in addition silica white, and dry method loading crosses silica gel column purification, uses NH3· H2O、CH3OH and CH2Cl2Gradient elution collects product, is spin-dried for, is dried in vacuo to obtain product 2-72 (46.2mg, yield 84.5%).1H-NMR(400MHz,CDCl3) δ 7.18-7.10 (m, 2H), 7.05 (d, J=8Hz, 1H), 6.95-6.76 (m, 4H), 3.94 (t, J=6Hz, 2H), 3.10-3.02 (m, 4H), 2.71-2.59 (m, 4H), 2.58-2.50 (m, 2H), 3.46 (s, 3H)；+c ESI Q1MS[M+H+]373.23。
Embodiment 17 prepares 7-4
7-2：
Boc-Gly (0.8453g, 4.8251mmol) is taken to be placed in 500mL flasks, addition 2-30-4 (1.6955g, 4.3865mmol), HBTU (2.4693g, 6.5798mmol) and HOBT (0.8891g, 6.5798mmol)；It is dripped under the conditions of 0 DEG C Add DIEA (3.4384mL, 19.7393mmol), goes to after 30 minutes and be stirred overnight at room temperature.Reaction solution is directly poured into saturation NaHCO3It in solution (500mL), is extracted with ethyl acetate (500mL+200mL × 3+100mL), merges organic phase, first with saturation NaHCO3Solution cleans (300mL × 2), then is cleaned (300mL × 2) with saturated salt solution；The anhydrous MgSO of organic phase4It is dry, mistake Filter, into filtrate, solid solution is made in addition silica white, and dry method loading crosses silica gel column purification, with ethyl acetate and petroleum ether gradient Elution collects product, is spin-dried for, is dried in vacuo to obtain product 7-2 (2.3893g, yield 100%).1H-NMR(400MHz,CDCl3)δ 7.20-7.10(m,2H),7.08-7.02(m,1H),6.96-6.86(m,2H),6.85-6.78(m,2H),4.88-4.81(m, 1H),3.96-3.91(m,2H),2.75-2.65(m,2H),2.60-2.50(m,2H),2.47(s,3H),2.40-2.25(m, 2H),2.02-1.84(m,4H),1.82-1.63(m,4H),1.45(s,9H)；+c ESI Q1MS:[M+H+]544.32。
7-4：
7-2 (2.3082g, 4.2453mmol) is placed in 200mL flasks, CH is added2Cl2(15mL), under magnetic agitation plus Enter TFA (3.25mL, 42.4527mmol), is stirred overnight at room temperature.It is spin-dried for, by crude product CH3OH dissolves, and NaHCO is added3In With extra TFA, filtering, into filtrate, solid solution is made in addition silica white, and dry method loading crosses silica gel column purification, uses NH3· H2O、CH3OH and CH2Cl2Gradient elution collects product, is spin-dried for, is dried in vacuo to obtain product 7-4 (896.6mg, yield 47.7%).1H-NMR(400MHz,CDCl3)δ7.18-7.10(m,2H),7.08-7.02(m,1H),6.94-6.87(m,2H),6.85-6.78 (m, 2H), 4.85-4.77 (m, 1H), 3.92 (t, J=4Hz, 2H), 3.41 (s, 2H), 2.72-2.62 (m, 2H), 2.52-2.43 (m,5H),2.29-2.16(m,2H),2.00-1.83(m,4H),1.73-1.62(m,4H)。
Embodiment 18 prepares 7-86,7-92,7-147
7-82：
It takes 2- methyl mercaptos phenthazine (10.1029g, 41.2362mmol) to be placed in 500mL flasks, is added through anhydrous K2CO3 Dried THF (200mL), in N2The lower mineral oil guard for being successively added 60% of protection NaH (6.5978g, 164.9448mmol) and 7-80 (12.0956g, 41.2362mmol).It is refluxed overnight under the conditions of 60 DEG C.It is cooled to room temperature, it will Reaction solution pours into mixture of ice and water, is extracted with ethyl acetate (500mL × 3), merges the anhydrous MgSO of organic phase4It is dry, mistake Filter, into filtrate, solid solution is made in addition silica white, and dry method loading crosses silica gel column purification, with ethyl acetate and petroleum ether gradient Elution, is spin-dried for, is dried in vacuo to obtain product 7-82 (19.1176g, yield 100%).1H-NMR(500MHz,CDCl3)δ7.18- 7.12(m,2H),7.08-7.03(m,1H),6.96-6.89(m,1H),6.88-6.80(m,2H),6.79-6.74(m,1H), 4.41 (s, 1H), 4.10-3.95 (m, 1H), 3.94-3.75 (m, 2H), 2.80 (t, J=15Hz, 1H), 2.46 (s, 3H), 2.28-2.14(m,1H),1.94-1.82(m,1H),1.61-1.53(m,3H),1.51-1.34(m,12H).7-86：
In 100mL flasks, 7-82 (19.00g, 41.5459mmol) is dissolved in dichloromethane (20mL), TFA is added (15.92mL, 207.7297mmol), is stirred at room temperature overnight.It is spin-dried for, crude product is dissolved with methanol, is then added NaHCO3Extra TFA is neutralized, is filtered, silica white is added into filtrate, solid solution is made, cross silica gel column purification.Use NH3· H2O、CH3OH and CH2Cl2Gradient elution collects product, is spin-dried for, is dried in vacuo to obtain product 7-86 (19.0062g, yield 100%).1H-NMR(500MHz,CDCl3)δ7.20-7.13(m,2H),7.11-7.06(m,1H),6.98-6.92(m,1H), 6.88-6.82 (m, 2H), 6.80-6.77 (m, 1H), 3.96 (t, J=7.5Hz, 2H), 3.22-3.12 (m, 1H), 3.00-2.92 (m,1H),2.74-2.64(m,1H),2.46(s,3H),2.25-2.13(m,1H),2.02-1.90(m,1H),1.85-1.75 (m,1H),1.72-1.55(m,3H),1.54-1.33(m,2H)。
7-88：
Boc-Gly (10.2309g, 58.4025mmol) is taken to be placed in 500mL flasks, addition 7-86 (18.9118g, 53.0932mmol), HBTU (29.8880g, 79.6398mmol), HOBT (10.9609g, 79.7398mmol) and DMF (200mL) DIEA (41.62mL, 238.9194mmol) is added dropwise under the conditions of 0 DEG C, goes to after 30 minutes and is stirred overnight at room temperature. Reaction solution is directly poured into saturation NaHCO3In solution (500mL), (500mL+200mL × 3+100mL) is extracted with ethyl acetate, Merge organic phase saturation NaHCO3Solution cleans (300mL × 2), then is cleaned (300mL × 2) with saturated common salt aqueous solution.Have Machine is mutually with anhydrous MgSO4Dry, filtering, into filtrate, solid solution is made in addition silica white, crosses silica gel column purification.With acetic acid second Ester and petroleum ether gradient elution collect product, are spin-dried for, are dried in vacuo to obtain product 7-88 (19.1364g, yield 70.2%).1H- NMR(500MHz,CDCl3)δ7.22-7.02(m,3H),6.97-6.89(m,1H),6.88-6.80(m,2H),6.79-6.70 (m,1H),4.05-3.80(m,4H),3.75-3.65(m,1H),3.60-3.40(m,1H),3.14-3.05(m,1H),2.47 (s,3H),2.25-2.10(m,1H),1.95-1.85(m,1H),1.62-1.30(m,15H)。
7-92：
7-88 (19.0825g, 37.1703mmol) is placed in 200mL flasks, dichloromethane (20mL) is added and dissolves, so TFA (14.24mL, 185.8516mmol) is added afterwards, is stirred overnight at room temperature.It is spin-dried for, crude product is dissolved with methanol, be added NaHCO3Neutralize extra TFA.Filtering, into filtrate, solid solution is made in addition silica white, crosses silica gel column purification.Use NH3· H2O, methanol and dichloromethane gradient elution, collect product, are spin-dried for, are dried in vacuo to obtain product 7-92 (13.6454g, yield 89.05%).1H-NMR(500MHz,CDCl3)δ7.24-7.10(m,2H),7.08-7.03(m,1H),7.00-6.77(m,3H), 6.76-6.70(m,1H),3.93-3.81(m,2H),3.65-3.47(m,2H),3.40-3.32(m,1H),3.26-3.19(m, 1H),3.13-3.04(m,1H),2.46(s,3H),2.25-2.05(m,2H),1.70-1.28(m,6H)。
7-145：
Boc-Gly (2.7978g, 15.9708mmol) is taken to be placed in 500ml flasks, addition 7-92 (6.00g, 14.5189mmol), HBTU (8.1732g, 21.7784mmol), HOBT (2.9427g, 21.7784mmol) and DMF (200mL)； DIEA (11.38mL, 65.3351mmol) is added dropwise under the conditions of 0 DEG C, goes to after 30 minutes and is stirred overnight at room temperature.By reaction solution Directly pour into saturation NaHCO3It in solution (500mL), is extracted with ethyl acetate (500mL+200mL × 3+100mL), merges organic Mutually with saturation NaHCO3Solution cleans (200mL × 2), then is cleaned (200mL × 2) with saturated salt solution；Organic phase is with anhydrous MgSO4Dry, filtering, into filtrate, solid solution is made in addition silica white, crosses silica gel column purification.With ethyl acetate and petroleum ether Gradient elution collects product, is spin-dried for, is dried in vacuo to obtain product 7-145 (7.67g, yield 93%).1H-NMR(500MHz, CDCl3)δ7.22-6.60(m,9H),5.03-4.93(m,1H),4.05-3.70(m,6H),2.45(s,3H),1.72-1.56 (m,6H),1.48(s,9H)。
7-147：
7-145 (7.57g, 13.2706mmol) is placed in 500mL flasks, dichloromethane (20mL) is added and dissolves, then TFA (10.17mL, 132.7057mmol) is added, is stirred overnight at room temperature.It is spin-dried for, crude product is dissolved with methanol, is then added NaHCO3Extra TFA is neutralized, is filtered, silica white is added into filtrate, solid solution is made, dry method loading crosses silica gel column purification, Use NH3·H2O, methanol and dichloromethane gradient elution, collect product, are spin-dried for, and are dried in vacuo to obtain product 7-147 (5.3975g, production Rate 86.48%).1H-NMR(500MHz,CDCl3)δ7.80-7.55(m,1H),7.22-7.09(m,2H),7.08-7.02(m, 1H),6.97-6.89(m,1H),6.87-6.79(m,2H),6.79-6.69(m,1H),5.03-4.94(m,1H),4.08-4.01 (m,1H),3.96-3.85(m,2H),3.84-3.65(m,1H),3.58-3.47(m,1H),3.40-3.29(m,2H),3.16- 3.06(m,1H),2.47(s,3H),2.27-2.08(m,1H),1.95-1.82(m,1H),1.62-1.13(m,6H)；ITMS+c ESI[M+H+]571.19,[M+Na+]593.31。
Embodiment 19 prepares 6-78
6-71：
Under nitrogen protection, 2- chloro phenothiazines (5.00g, 21.3mmol) are added in 500ml flasks, are dissolved with THF, so The NaH (4.2786g, 106.966mmol) of 60% mineral oil guard is added afterwards, releases a large amount of bubbles, the bromo- 3- of 1- are then added Chloropropane (10.57mL, 106.966mmol).It is refluxed overnight in 65 DEG C of oil bath.Stop reaction, reaction solution is poured into ice water It in mixture (500mL), is extracted with ethyl acetate (300mL × 3), merges organic phase and dried with anhydrous magnesium sulfate, filtered.Column layer Analysis is collected product point, product 6-71 (6.6377g, yield is concentrated under reduced pressure to obtain with ethyl acetate and petroleum ether gradient elution 59.11%).+c ESI Q1 MS：[M+H+]310.10
6-78：
6-71 (500mg, 1.6117mmol) is added in cylinder bottle, piperidines -4- alcohol (244.5mg, 2.4175mmol) is used CH3CN (15mL) dissolves, and is eventually adding triethylamine (0.67mL, 4.8346mmol), and reflux 72 is small in 80 DEG C of oil baths after sealing When.It is spin-dried for, is then dissolved with methanol, NaHCO is added3It neutralizes, filtering.Column chromatography, with triethylamine, ethyl acetate and petroleum ether ladder Degree elution, collects product point, is concentrated under reduced pressure, is dried in vacuo to obtain product 6-78 (541.6mg, yield 89.6%).1H-NMR (400MHz,CDCl3) δ 7.18-7.09 (m, 2H), 7.01 (d, J=8Hz, 1H), 6.95-6.83 (m, 4H), 3.89 (t, J= 6Hz, 2H), 3.72-3.62 (m, 1H), 2.78-2.68 (m, 2H), 2.46 (t, J=6Hz, 2H), 2.20-2.06 (m, 2H), 1.98-1.83(m,4H),1.59-1.50(m,2H)。
Embodiment 20 prepares 6-80
6-71 (500mg, 1.6117mmol) and prolinol (244.5mg, 2.4175mmol) are added in cylinder bottle, uses CH3CN (15mL) dissolves, and is eventually adding triethylamine (0.67mL, 4.8346mmol), and reflux 72 is small in 80 DEG C of oil baths after sealing When.Stop reaction, be directly evaporated, then dissolved with methanol, NaHCO is added3It neutralizes, filters, concentration.Column chromatography, with acetic acid second Ester and petroleum ether gradient elution, collect product point, and reduced pressure is dried in vacuo to obtain product 6-80 (307.1mg, yield 50.8%) 。1H-NMR(400MHz,CDCl3)δ7.20-7.12(m,2H),7.06-7.01(m,1H),6.97-6.92(m,1H),6.92- 6.87 (m, 2H), 6.86-6.83 (m, 1H), 3.92 (t, J=6Hz, 2H), 3.60-3.55 (m, 1H), 3.36-3.31 (m, 1H), 3.19-3.13(m,1H),2.97-2.89(m,1H),2.59-2.52(m,1H),2.40-2.32(m,1H),2.24-2.16(m, 1H),2.06-1.90(m,3H),1.87-1.81(m,1H),1.77-1.68(m,3H)。
Embodiment 21 prepares 6-86
6-71 (500mg, 1.6117mmol) is added in cylinder bottle, guanidine hydrochloride (168.4mg, 1.7728mmol) uses second Alcohol/water (10mL) dissolves sodium hydroxide (70.9mg, 1.7728mmol), then flows back 72 hours in 80 DEG C of oil baths.Stop anti- It answers, is directly evaporated.Column chromatography is eluted with ammonium hydroxide, methanol and dichloromethane gradient, collects product, and reduced pressure is dried in vacuo Product 6-86 (513.9mg, yield 100%).1H-NMR(400MHz,CDCl3) δ 7.23-7.14 (m, 2H), 7.07 (d, J= 8Hz, 1H), 7.00-6.88 (m, 4H), 3.97 (t, J=6Hz, 2H), 3.28-3.19 (m, 2H), 2.10-2.02 (m, 2H).
Embodiment 22 prepares 6-87
The addition 6-71 (500mg, 1.6117mmol) in cylinder bottle, 1,2,4- triazoles (222.6mg, 3.2234mmol), it is dissolved with acetone (5mL), potassium carbonate (1.3365g, 9.6701mmol) and potassium iodide is then added (18.7mg, 0.1612mmol) then flows back 72 hours in 80 DEG C of oil baths.Stop reaction, is directly evaporated.Column chromatography uses second Product is collected in acetoacetic ester and petroleum ether gradient elution, is concentrated under reduced pressure, is dried in vacuo to obtain product 6-87 (552.6mg, yield 100%).1H-NMR(400MHz,CDCl3) δ 7.90 (s, 1H), 7.81 (s, 1H), 7.23-7.14 (m, 2H), 7.10 (d, J= 8Hz, 1H), 7.02-6.91 (m, 2H), 6.84-6.76 (m, 2H), 4.26 (t, J=6Hz, 2H), 3.78 (t, J=6Hz, 2H), 2.42-2.34(m,2H)。
Embodiment 23 prepares 6-88
6-71 (500mg, 1.6117mmol) and tetrazole (225.7mg, 3.2234mmol) are added in cylinder bottle, with third Ketone (5mL) dissolves, and potassium carbonate (1.3365g, 9.6701mmol) and potassium iodide (18.7mg, 0.1612mmol) is then added, so It flows back 72 hours in 80 DEG C of oil baths afterwards.Stop reaction, is directly evaporated.Column chromatography, petroleum ether and ethyl acetate gradient elution, are received Collect product, is concentrated under reduced pressure, is dried in vacuo to obtain product 6-88 (554.2mg, yield 43.09%).1H-NMR(400MHz,CDCl3)δ 8.47 (s, 1H), 7.21-7.15 (m, 2H), 7.08 (d, J=8Hz, 1H), 7.01-6.91 (m, 2H), 6.85-6.78 (m, 2H), 4.77 (t, J=6Hz, 2H), 3.97 (t, J=6Hz, 2H), 2.55-2.47 (m, 2H).
Embodiment 24 prepares 6-89
The addition 6-71 (500mg, 1.6117mmol) in cylinder bottle, 5- methyl-1 H- tetrazoles (270.7mg, 3.2234mmol), it is dissolved with acetone (5mL), potassium carbonate (1.3365g, 9.6701mmol) and potassium iodide is then added (18.7mg, 0.1612mmol) then flows back 72 hours in 80 DEG C of oil baths.Stop reaction, is directly evaporated.Column chromatography uses stone Oily ether and ethyl acetate gradient elution, collect product, are concentrated under reduced pressure, are dried in vacuo to obtain product 6-89 (511.4mg, yield 88.67%).1H-NMR(400MHz,CDCl3) δ 7.20-7.14 (m, 2H), 7.07 (d, J=8Hz, 1H), 7.00-6.90 (m, 2H), 6.86-6.77 (m, 2H), 4.68 (t, J=6Hz, 2H), 3.95 (t, J=6Hz, 2H), 2.51-2.44 (m, 5H).:
Embodiment 25 prepares 6-109
6-81：
The addition 6-71 (500mg, 1.6117mmol) in cylinder bottle, 1- tert-butoxycarbonyl-piperazines (244.5mg, 2.4175mmol), use CH3CN (15mL) dissolves, and is eventually adding triethylamine (0.67mL, 4.8346mmol), rapid to seal, so It flows back 72 hours in 80 DEG C of oil baths afterwards.Stop reaction, be directly evaporated, then dissolved with methanol, NaHCO is added3It neutralizes, mistake Filter, concentration.Column chromatography collects product with ethyl acetate and petroleum ether gradient elution, is concentrated under reduced pressure, is dried in vacuo to obtain product 6- 81 (741.4mg, yield 100%) ITMS+ESI:[M+H+]460.19。
6-109：
In the flask of 50mL, 6-81 (877.7mg, 1.9079mmol) is added, dissolves (10mL) with dichloromethane, then TFA (0.73mL, 9.5395mmol) is added, is stirred overnight at room temperature.Stop reaction being evaporated, is dissolved with methanol, be then added Measure NaHCO3Extra TFA is neutralized, is filtered, silica white concentration is added into filtrate and is evaporated, dry method loading column chromatography.With ammonium hydroxide, Methanol and dichloromethane gradient elution, collect product point, product 6-109 (558.3mg, yield 81%) are concentrated under reduced pressure to obtain.1H- NMR(400MHz,CDCl3) δ 7.18-7.09 (m, 2H), 7.01 (d, J=8Hz, 1H), 6.95-6.83 (m, 4H), 3.91 (t, J =6Hz, 2H), 2.95-2.88 (m, 4H), 2.51-2.42 (m, 6H), 1.97-1.88 (m, 2H).
Embodiment 26 prepares 4-219
4-195：
It takes 2- chloro phenothiazines (1.00g, 4.2786mmol) to be placed in 100mL three neck round bottom, is added through Carbon Dioxide The dried THF of potassium (25mL), in N2The lower NaH (410.7mg, 17.1145mmol) that 60% mineral oil guard is added of protection and 4-170 (1.2550g, 4.2786mmol), is refluxed overnight under 60 DEG C of heating conditions.After reaction, stop reaction, be cooled to Reaction solution is poured into ice water (200mL), is extracted with ethyl acetate (200mL × 3) by room temperature, merges organic phase anhydrous slufuric acid Magnesium is dried, filtering, and silica white is added in filtrate, and solid solution, dry method loading column chromatography, with ethyl acetate and stone are made in drying Oily ether gradient elution collects product, is evaporated to obtain sterling 4-195 (0.70g, yield 47%).ITMS+c ESI：[M+H+] 445.17.4-219：
It takes 4-195 (1.50g, 3.1444mmol) to be placed in 100mL flasks, dichloromethane (50mL) is added, is stirred in magnetic force Lower addition TFA (2.41mL, 31.4436mmol) is mixed, at room temperature reaction overnight.Stopping reaction being evaporated, crude product is dissolved with methanol, Excess NaHCO is added3TFA is neutralized, filtering is added dichloromethane and dissolves set product, wet method loading column chromatography.Use NH3·H2O、 Methanol and dichloromethane gradient elution, collect product, and concentration is dried to obtain product 4-219 (654.4mg, yield 60%).1H- NMR(500MHz,CDCl3)δ7.20-7.165(m,2H),7.09-7.055(m,1H),7.00-6.95(m,1H),6.95- 6.915(dd,1H),6.91-6.87(d,1H),6.865-6.85(d,1H),4.00-3.94(t,2H),3.81-3.42(m, 2H),2.975-2.9425(s,1H),2.9025-2.8675(s,1H)2.26-2.12(m,1H),2.005-1.8975(m,1H), 1.768-1.665(m,2H),1.635-1.505(m,2H),1.495-1.40(m,2H)；ITMS+c ESI：[M+H+]345.22。
Biological test and result
This patent is directed to the cell of MCF-7 cell strainHJ2mm and Human hepatoma cell line Hep-G2 to synthesized compound Toxicity has carried out detailed test.Culture medium used in MCF-7 and Hep-G2 cell strains is to contain 10%NCS, and 1% is dual anti- DMEM-F12, inSolution.Cell is cultivated to its exponential phase of growth, cell suspension is counted using cell counting board, uses culture solution Adjusting cell concentration is 20000/mL, then by cell suspension inoculation to 96 orifice plates, 100 μ L is inoculated with per hole, and reserve 4 Then culture plate is positioned over 5%CO by hole as blank control2, cultivate 24 hours in 37 DEG C of incubators and keep cell adherent.It takes out Culture plate removes culture solution therein, then sequentially add each concentration (weigh each compound in the desired amount, then will be each A compound first with 50 μ lDMSO dissolvings, is then diluted to 100 μm of ol/L, 50 μm of ol/L, 25 μm of ol/ successively with blank culture solution L, 12.5 μm of ol/L, 6.25 μm of ol/L, 3.125 μm of ol/L, 1.5625 μm of ol/L) drug containing culture solution, blank control wells add Enter blank culture solution, is put into incubator and continues culture 72 hours.By known anticancer drugs, doxorubicin, taxol respectively with this hair The compound of bright preparation makees positive control, takes out culture plate, the MTT reagents (20 holes μ L/) of 5mg/mL are separately added into corresponding aperture, Culture plate is relay into people 5%CO again2, continue culture 4 hours in 37 DEG C of incubators, culture plate is taken out, by the training in all holes Nutrient solution removes, and DMSO (150 holes μ L/) is then added, measures the OD of cell at wavelength 490nm using enzyme-linked immunosorbent assay instrument Value, then uses IC50Software for calculation calculates the IC of each compound50Value, as shown in table 2.According to the present invention, not expected hair Existing, the compound that the present invention prepares gained will produce MCF-7 and Hep-G2 cell strains certain inhibiting effect.
2 phenothiazine compound IC of table50Value

Claims (3)

1. a kind of application of phenothiazine compound, which is characterized in that be used to prepare and meanwhile anti-human breast cancer cell line mcf-7 and The drug of anti-human liver cancer cell strain Hep-G2, shown in the compound structure such as general formula (I)：
Wherein, R C2-3Straight chain saturated alkyl；B can be independently Cl, methyl mercapto or trifluoromethyl；When B is methyl mercapto, A For triazol radical, tetrazole base, pyrrole radicals, guanidine radicals, morpholinyl；When B is trifluoromethyl, A is morpholinyl, pyrrole radicals；When B is When Cl, A is triazol radical, tetrazole base, pyrrole radicals, guanidine radicals, morpholinyl.
2. a kind of anticancer pharmaceutical composition, which is characterized in that wherein contain phenothiazines shown in claim 1 formula of (I) Compound is as active ingredient and one or more pharmaceutically acceptable carriers；The wherein anticancer pharmaceutical composition Can simultaneously anti-human breast cancer cell line mcf-7 and anti-human liver cancer cell strain Hep-G2.
3. a kind of anticancer pharmaceutical composition as claimed in claim 2, which is characterized in that can be made into pharmaceutically acceptable injection Agent, spray, inhalant or oral agents.
CN201510271507.5A 2015-05-25 2015-05-25 Phenothiazine compound and its preparation method and application Expired - Fee Related CN104829554B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510271507.5A CN104829554B (en) 2015-05-25 2015-05-25 Phenothiazine compound and its preparation method and application

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201510271507.5A CN104829554B (en) 2015-05-25 2015-05-25 Phenothiazine compound and its preparation method and application

Publications (2)

Publication Number Publication Date
CN104829554A CN104829554A (en) 2015-08-12
CN104829554B true CN104829554B (en) 2018-07-13

Family

ID=53807797

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201510271507.5A Expired - Fee Related CN104829554B (en) 2015-05-25 2015-05-25 Phenothiazine compound and its preparation method and application

Country Status (1)

Country Link
CN (1) CN104829554B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9695138B1 (en) * 2016-10-17 2017-07-04 Acenda Pharma, Inc. Phenothiazine derivatives and methods of use thereof
CN108530384B (en) * 2018-03-26 2021-12-28 南京泽恒医药技术开发有限公司 Preparation method of prochlorperazine
CA3094481A1 (en) 2018-04-06 2019-10-10 Camp4 Therapeutics Corporation Phenothiazine derivatives and uses thereof
EP3574920A1 (en) * 2018-05-31 2019-12-04 Institut National De La Sante Et De La Recherche Medicale (Inserm) Nupr1 inhibition for treating cancer
CN109761932A (en) * 2019-01-29 2019-05-17 天津国际生物医药联合研究院 Phenothiazine compound and its application
IT201900015809A1 (en) * 2019-09-06 2021-03-06 Univ Degli Studi Padova COMPOUNDS SIMILAR TO THYORIDAZINE
CN113264903A (en) * 2021-05-27 2021-08-17 郑州大学 Phenothiazine compound and preparation method and application thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013060305A1 (en) * 2011-10-28 2013-05-02 Huang Chiying Pharmaceutical composition for elimination of cancer stem cells
CN102516200B (en) * 2011-12-14 2014-03-12 合肥工业大学 Hybrid compound with indanone and phenothiazine as skeletal structures and application thereof

Also Published As

Publication number Publication date
CN104829554A (en) 2015-08-12

Similar Documents

Publication Publication Date Title
CN104829554B (en) Phenothiazine compound and its preparation method and application
US11529341B2 (en) Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation
TWI280962B (en) 6-alkenyl-, 6-alkinyl-and 6-epoxy-epothilone derivatives process for their production and their use in pharmaceutical preparations
CN109863146A (en) Aryl-linking compound as immunomodulator
AU2015232543A9 (en) 1,3-benzodioxole derivative
JP2010519337A (en) Carbamate compounds
JP2022547952A (en) BRD9 bifunctional degradation inducer and method of use thereof
CN103781783A (en) Piperazine-substituted benzothiophene derivatives as antipsychotic agents
US11104661B1 (en) Inhibiting human integrin (α-4) (β-7)
JP7348665B2 (en) Substituted benzothiophene analogs as selective estrogen receptor degraders
MX2010013915A (en) Thiazolyl piperdine derivatives.
CA2960910A1 (en) Nitrogen-containing analogs of salinomycin, synthesis and use against cancer stem cells and malaria
CN110343033B (en) Magnolol series derivatives, and preparation method and application thereof
CN109678815B (en) N-benzyl benzamide derivative and preparation method and pharmaceutical application thereof
CN105175360B (en) Ether-type aryl bridged piperazine derivatives and its salt, preparation method and purposes
WO2014056083A1 (en) Kinase inhibitors and method of treating cancer with same
CN101903337A (en) Antineoplastic compound
CN1931869B (en) Derivative of 5-deoxy-5-fluoro cytidine and its preparation process and use
CN107011312B (en) Jungermanniaceae D nitrogen containing derivative and preparation method thereof and the purposes in treatment tumor disease
CN113698390B (en) Compounds useful as RET kinase inhibitors and uses thereof
CA3190686A1 (en) Heterocyclic compound as bcl-2 inhibitor
CN104337812A (en) Substituted heteroaryl compound as well as use method and application thereof
EA014905B1 (en) Novel processes for the preparation of piperazinyl benzamide derivatives
CN112624949B (en) Chiral diaryl-beta-lactam compound, preparation method and pharmaceutical application thereof
CN106946974B (en) Ursolic amide derivative containing pyrazole heterocycle and synthesis and application thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
EXSB Decision made by sipo to initiate substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20180713

Termination date: 20210525

CF01 Termination of patent right due to non-payment of annual fee